Eli Lilly ($LLY@US) raised its 2021 profit forecast on Tuesday as it increased sales of its COVID-19 antibody therapies. While the company is best known as the developer and marketer of Prozac, it is also hoping to obtain approval for other drugs. These drugs include an experimental type-2 diabetes drug and a highly anticipated Alzheimer’s drug known only as Donanemab. Eli Lilly shares are up 45% overall in 2021, and the stock rose over half a percent in early trading Tuesday.